1.1Add a dopamine partial agonist
The prescriber adds aripiprazole to the ongoing antidepressant regimen. Follow-up visits track depressive symptoms and assess restlessness and other movement symptoms during dose adjustment.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The prescriber adds aripiprazole to the ongoing antidepressant regimen. Follow-up visits track depressive symptoms and assess restlessness and other movement symptoms during dose adjustment.
A figure-eight coil delivers repeated magnetic pulses over the left dorsolateral prefrontal cortex. The operator sets pulse intensity relative to the patient's motor threshold and repeats sessions on a scheduled course.
The therapist and patient use activity schedules and thought records to identify patterns associated with depressed mood. Between sessions, the patient carries out planned activities and records changes in mood and daily functioning.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A psychiatric day hospital enrolls adults with major depressive disorder whose symptoms persist despite antidepressant treatment. Participants continue their prescribed antidepressant and receive adjunctive ulotaront under a research protocol. Nursing staff record doses taken during program hours and reconcile home doses at the next visit.
A research protocol uses bupropion as the background antidepressant for adults with major depressive disorder who show an inadequate response to an adequate course of bupropion. The protocol adds ulotaront as a separate oral medication and keeps the established bupropion dose fixed during the assessment period unless a clinician changes treatment. The study record tracks administration, depressive symptoms, and adverse events for each participant.
Adults with an inadequate antidepressant response continue their antidepressant when adjunctive ulotaront begins. Participants complete a nine-item depression questionnaire 7 days before the first adjunctive dose and again immediately before that dose on day 0. They repeat the questionnaire on days 7, 14, and 28, and the study software calculates each follow-up score's change from the mean of the two baseline scores.
A supervised treatment unit enters the ongoing antidepressant and adjunctive ulotaront as separate orders in its electronic medication administration record. A nurse scans the participant's wristband and each unit-dose package at administration. The record links the administration time and dose status to the corresponding order and records a reason for each missed dose.
Screening software retrieves antidepressant orders, documented dose changes, and dated depression questionnaire scores from the electronic health record. It pairs pretreatment and follow-up scores from the same questionnaire and flags records that meet the research protocol's requirements for treatment duration and persistent symptoms. A clinician verifies medication exposure and symptom history before confirming eligibility for adjunctive ulotaront alongside the ongoing antidepressant.
Each participant receives separate bottles with electronic caps for the background antidepressant and adjunctive ulotaront. The caps log opening times, and a participant diary records dose times and doses removed in advance. Study software aligns both data sources with scheduled dose times and flags discrepancies for staff review.
The patient takes the ongoing antidepressant tablet and a separate immediate-release tablet containing ulotaront. Separate dosage units allow adjustment of the ulotaront dose while the antidepressant dose stays fixed.
A hard capsule contains a measured quantity of a pharmaceutically acceptable ulotaront salt blended with microcrystalline cellulose. The capsule strength is expressed as the mass of ulotaront it provides, and the patient takes the antidepressant in a separate dosage unit.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The present invention is further directed to a method for the treatment of treatment-refractory or treatment-resistant depression (TRD) comprising administering to a patient in need thereof, combination therapy with a therapeutically effective amount of esketamine and at least one antidepressant, as herein defined.A · US 2013/0236573 A1 · ¶ 14
A method for treating therapy refractory depression, comprising co-administering an inhibitor of 11-beta-HSD-2 or metabolites thereof with an antidepressant drug.B · US 2019/0099393 A1 · claim 20
An empty cell means only that no passage was reproduced there.
Moreover, about approximately 30% of depressed patients remain partially or totally treatment-resistant to at least two antidepressant treatments including combination treatments.A · US 2013/0236573 A1 · ¶ 5
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least one antidepressant.A · US 2013/0236573 A1 · ¶ 2
Therefore, there is a need to identify patients, which do not respond to currently used antidepressants as early as possible and apply a differentiated treatment strategy.B · US 2019/0099393 A1 · ¶ 7
Another embodiment of the method combines the described compounds with forms of Magnesium salts in order to overcome longer term tolerability issues with the compounds, which are in the center of the invention.B · US 2019/0099393 A1 · ¶ 6
patent.fyi, US 2026/0355150 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355150/, SHA-256 30082790c220d6849aca3f51de1e472ea4601015a14efbf6f96e61c1ec1d3c8c